GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » Cyclically Adjusted Price-to-FCF

NovoCure (FRA:038) Cyclically Adjusted Price-to-FCF : (As of May. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is NovoCure Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


NovoCure Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for NovoCure's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Cyclically Adjusted Price-to-FCF Chart

NovoCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NovoCure Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NovoCure's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, NovoCure's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NovoCure's Cyclically Adjusted Price-to-FCF falls into.



NovoCure Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

NovoCure's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, NovoCure's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.183/129.4194*129.4194
=-0.183

Current CPI (Dec. 2023) = 129.4194.

NovoCure Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 -0.386 99.621 -0.501
201506 -0.282 100.684 -0.362
201509 -0.266 100.392 -0.343
201512 -0.320 99.792 -0.415
201603 -0.360 100.470 -0.464
201606 -0.376 101.688 -0.479
201609 -0.398 101.861 -0.506
201612 -0.187 101.863 -0.238
201703 -0.314 102.862 -0.395
201706 -0.072 103.349 -0.090
201709 0.007 104.136 0.009
201712 -0.046 104.011 -0.057
201803 -0.171 105.290 -0.210
201806 -0.084 106.317 -0.102
201809 0.040 106.507 0.049
201812 0.142 105.998 0.173
201903 -0.062 107.251 -0.075
201906 0.061 108.070 0.073
201909 0.103 108.329 0.123
201912 0.035 108.420 0.042
202003 -0.010 108.902 -0.012
202006 0.078 108.767 0.093
202009 0.220 109.815 0.259
202012 0.353 109.897 0.416
202103 0.113 111.754 0.131
202106 0.189 114.631 0.213
202109 0.173 115.734 0.193
202112 0.001 117.630 0.001
202203 -0.077 121.301 -0.082
202206 0.105 125.017 0.109
202209 0.161 125.227 0.166
202212 -0.091 125.222 -0.094
202303 -0.202 127.348 -0.205
202306 -0.258 128.729 -0.259
202309 -0.233 129.860 -0.232
202312 -0.183 129.419 -0.183

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NovoCure  (FRA:038) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


NovoCure Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of NovoCure's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure (FRA:038) Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (FRA:038) Headlines

No Headlines